Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Standard
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. / Witzel, Isabell; Loibl, S; von Minckwitz, G; Eidtmann, H; Fehm, T; Khandan, F; Schmatloch, S; Hauschild, M; Bischoff, J; Fasching, P A; Mau, C; Schem, C; Rack, B; Meinhold-Heerlein, I; Liedtke, C; Karn, T; Huober, J; Zu Eulenburg, Christine Gräfin; Issa-Nummer, Y; Untch, M; Müller, Volkmar.
in: BRIT J CANCER, Jahrgang 107, Nr. 6, 6, 2012, S. 956-960.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
AU - Witzel, Isabell
AU - Loibl, S
AU - von Minckwitz, G
AU - Eidtmann, H
AU - Fehm, T
AU - Khandan, F
AU - Schmatloch, S
AU - Hauschild, M
AU - Bischoff, J
AU - Fasching, P A
AU - Mau, C
AU - Schem, C
AU - Rack, B
AU - Meinhold-Heerlein, I
AU - Liedtke, C
AU - Karn, T
AU - Huober, J
AU - Zu Eulenburg, Christine Gräfin
AU - Issa-Nummer, Y
AU - Untch, M
AU - Müller, Volkmar
PY - 2012
Y1 - 2012
N2 - We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.
AB - We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Multivariate Analysis
KW - Treatment Outcome
KW - Predictive Value of Tests
KW - Enzyme-Linked Immunosorbent Assay
KW - Drug Administration Schedule
KW - Tumor Markers, Biological/blood
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Antineoplastic Agents/administration & dosage/therapeutic use
KW - Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use
KW - Breast Neoplasms/blood/drug therapy
KW - Neoadjuvant Therapy/methods
KW - Quinazolines/administration & dosage/therapeutic use
KW - Receptor, erbB-2/blood
KW - Receptors, Estrogen/blood
KW - Translational Medical Research
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Multivariate Analysis
KW - Treatment Outcome
KW - Predictive Value of Tests
KW - Enzyme-Linked Immunosorbent Assay
KW - Drug Administration Schedule
KW - Tumor Markers, Biological/blood
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Antineoplastic Agents/administration & dosage/therapeutic use
KW - Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use
KW - Breast Neoplasms/blood/drug therapy
KW - Neoadjuvant Therapy/methods
KW - Quinazolines/administration & dosage/therapeutic use
KW - Receptor, erbB-2/blood
KW - Receptors, Estrogen/blood
KW - Translational Medical Research
M3 - SCORING: Journal article
VL - 107
SP - 956
EP - 960
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 6
M1 - 6
ER -